150 related articles for article (PubMed ID: 31662027)
1. Medium-Throughput Detection of Hsp90/Cdc37 Protein-Protein Interaction Inhibitors Using a Split
Siddiqui FA; Parkkola H; Manoharan GB; Abankwa D
SLAS Discov; 2020 Feb; 25(2):195-206. PubMed ID: 31662027
[TBL] [Abstract][Full Text] [Related]
2. Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.
Jiang Y; Bernard D; Yu Y; Xie Y; Zhang T; Li Y; Burnett JP; Fu X; Wang S; Sun D
J Biol Chem; 2010 Jul; 285(27):21023-36. PubMed ID: 20413594
[TBL] [Abstract][Full Text] [Related]
3. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.
He J; Niu X; Hu C; Zhang H; Guo Y; Ge Y; Wang G; Jiang Y
Protein Expr Purif; 2013 Nov; 92(1):119-27. PubMed ID: 24056254
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core.
Zhang Q; Wu X; Zhou J; Zhang L; Xu X; Zhang L; You Q; Wang L
Eur J Med Chem; 2021 Jan; 210():112959. PubMed ID: 33109397
[TBL] [Abstract][Full Text] [Related]
5. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.
Eckl JM; Rutz DA; Haslbeck V; Zierer BK; Reinstein J; Richter K
J Biol Chem; 2013 May; 288(22):16032-42. PubMed ID: 23569206
[TBL] [Abstract][Full Text] [Related]
6. Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
Sonamoto R; Kii I; Koike Y; Sumida Y; Kato-Sumida T; Okuno Y; Hosoya T; Hagiwara M
Sci Rep; 2015 Aug; 5():12728. PubMed ID: 26234946
[TBL] [Abstract][Full Text] [Related]
7. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S30. PubMed ID: 21342561
[TBL] [Abstract][Full Text] [Related]
8. The Therapeutic Potential of Targeting Hsp90-Cdc37 Interactions in Several Diseases.
Zhang X; Li S; Li Z; Cheng L; Liu Z; Wang C
Curr Drug Targets; 2022; 23(10):1023-1038. PubMed ID: 35400341
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and structural studies of the interaction of Cdc37 with Hsp90.
Zhang W; Hirshberg M; McLaughlin SH; Lazar GA; Grossmann JG; Nielsen PR; Sobott F; Robinson CV; Jackson SE; Laue ED
J Mol Biol; 2004 Jul; 340(4):891-907. PubMed ID: 15223329
[TBL] [Abstract][Full Text] [Related]
10. Rational design of peptide inhibitors targeting HSP90-CDC37 protein-protein interaction.
Zhang Q; Yan L; Zhang Y; Zhang L; Yu J; You Q; Wang L
Future Med Chem; 2024 Jan; 16(2):125-138. PubMed ID: 38189168
[No Abstract] [Full Text] [Related]
11. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
[TBL] [Abstract][Full Text] [Related]
12. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
13. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
14. Characterization of celastrol to inhibit hsp90 and cdc37 interaction.
Zhang T; Li Y; Yu Y; Zou P; Jiang Y; Sun D
J Biol Chem; 2009 Dec; 284(51):35381-9. PubMed ID: 19858214
[TBL] [Abstract][Full Text] [Related]
15. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.
Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K
J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315
[TBL] [Abstract][Full Text] [Related]
16. Cdc37 as a Co-chaperone to Hsp90.
Prince TL; Lang BJ; Okusha Y; Eguchi T; Calderwood SK
Subcell Biochem; 2023; 101():141-158. PubMed ID: 36520306
[TBL] [Abstract][Full Text] [Related]
17. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity.
Cheng CJ; Liu KX; Zhang M; Shen FK; Ye LL; Wu WB; Hou XT; Hao EW; Hou YY; Bai G
Acta Pharmacol Sin; 2022 Apr; 43(4):1046-1058. PubMed ID: 34326484
[TBL] [Abstract][Full Text] [Related]
18. Structure of an Hsp90-Cdc37-Cdk4 complex.
Vaughan CK; Gohlke U; Sobott F; Good VM; Ali MM; Prodromou C; Robinson CV; Saibil HR; Pearl LH
Mol Cell; 2006 Sep; 23(5):697-707. PubMed ID: 16949366
[TBL] [Abstract][Full Text] [Related]
19. The split Renilla luciferase complementation assay is useful for identifying the interaction of Epstein-Barr virus protein kinase BGLF4 and a heat shock protein Hsp90.
Wang J; Guo W; Long C; Zhou H; Wang H; Sun X
Acta Virol; 2016 Mar; 60(1):62-70. PubMed ID: 26982469
[TBL] [Abstract][Full Text] [Related]
20. Design of Disruptors of the Hsp90-Cdc37 Interface.
D'Annessa I; Hurwitz N; Pirota V; Beretta GL; Tinelli S; Woodford M; Freccero M; Mollapour M; Zaffaroni N; Wolfson H; Colombo G
Molecules; 2020 Jan; 25(2):. PubMed ID: 31952296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
